Table 1.

Summary of HMCD studies on human tumor cell lines and xenografts.

Tumor Type	Tumor Cell-Line	Heptamethine Cyanine Dye	Conjugate	References
Lung Cancer	A549, NCIH-460, H358, A549-DR	IR-783, IR-780, MHI-148	Methotrexate, Erlotinib	(50–57)
Breast Cancer	MCF-7, MDA231, LTED	IR-783, IR-780, MHI-148, DZ-1	Methotrexate, FTS, Genistein, Erlotinib	(51, 55–61)
Hepatoma	SMMC-7721, HepG2	IR-783, IR-780, MHI-148	Dasatinib, Methotrexate	(51, 53, 55, 62)
Cervical Cancer	HeLa	IR-783, IR-780, MHI-148		(51, 53, 60)
Prostate Cancer	PC-3, LNCap, C4-2, DU-145	IR-783, IR-780, IR786, MHI-148	MAOA inhibitor, Gemcitabine, Isoniazid	(53, 63–68)
Leukemia	K562	IR-783, MHI-148		(53, 63)
Pancreatic Cancer	MIA, PaCa-2	IR-783		(53)
Renal Cancer	SN12C, ACHN, Caki-1	IR-783, IR-780		(69)
Glioblastoma	U251, GL261, U87, T98T, LN18, Primary PDX	IR-780, IR783, DZ-1, IR-786	Gemcitabine, Crizotinib, Dasatinib, MAOA inhibitor, Rucaparib	(54, 70–76)
Osteosarcoma	MG-63	IR-780		(77)